Biotech has long been one of the strongest sector stories of the past year, and investors who got there early have been rewarded. As of April 2, 2026, the State Street SPDR S&P Biotech ETF (NYSE:XBI) ...

When it comes to beauty formulations that are inclusive of people and planet, finding a middle ground is not always easy. Natural ingredients often rely on farming practices that often require a lot ...

PITTSBURGH, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (KRYS) (the “Company”) (NASDAQ: KRYS) announced today that the United States Food and Drug Administration (FDA) granted platform ...

Two kernels, 100 years apart: One yielded 60 bushels per acre in 1927; the other topped 623. They look nearly identical on the outside, but a century of genetic innovation separates them under the ...

Debut Biotech, a company innovating new molecules, is partnering with Image Skincare to launch a new beauty product, CNBC has learned. The San Diego-based company uses biotechnology and artificial ...

Gilead Sciences has agreed to buy German clinical-stage biotechnology company Tubulis for up to $5 billion in a deal that bolsters the biopharmaceutical company’s oncology pipeline.

Under the agreement, Vertex will make a $15m upfront payment to Halozyme and potential future milestone payments.

Trinity Biotech plc announced a significant step in its transformation plan by appointing Barclays Capital Inc. as its exclusive financial advisor. The company is shifting its focus to developing its ...

MARTINSRIED, Germany--(BUSINESS WIRE)--SIRION Biotech GmbH announced today that Beam Therapeutics licensed rights to use SIRION Biotech’s LentiBOOST™ for use in their CAR-T cell products. CAR-T cell ...

The pharmaceutical industry is navigating one of its most disruptive periods in recent memory, according to Anthony Lakavage, ...

Bernhard running samples at the DARO lab at the BioTech Connector on the Nebraska Innovation Campus. Photo provided by DARO. DARO, a biotech startup in Lincoln centered around early disease detection ...

Whether the deal reaches its full value hinges on US regulatory milestones for Centessa’s lead candidate, cleminorexton.